·       Compared with tirzepatide, Wegovy^® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke or death from any cause, in people with overweight or obesity and cardiovascular disease (CVD) who stayed on treatment¹

·       Similarly, the study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy^® users compared with tirzepatide users in all treated people, regardless of any gaps in their treatment¹

·       This study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy^® are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments¹

Dubai, 1 September 2025 – Novo Nordisk today presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy^® (semaglutide 2.4 mg) compared with tirzepatide treatment in people with overweight or obesity and established CVD without diabetes.¹

Continue reading Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease →